NHS National Generic Pharmaceuticals - Lenalidomide
A Contract Award Notice
by NHS ENGLAND
- Source
- Find a Tender
- Type
- Framework (Goods)
- Duration
- not specified
- Value
- £1
- Sector
- HEALTH
- Published
- 30 Sep 2022
- Delivery
- not specified
- Deadline
- n/a
Related Terms
- pharmaceutical products
- nhs national generic pharmaceuticals
- leeds
- period of framework agreement
- nhs national generic pharmaceuticals - lenalidomide
- nhs national generic pharmaceuticals- lenalidomideoffer reference number
- nhs national generic pharmaceuticals - lenalidomideoffer reference number
- lenalidomide
- months.potential periods of call-offs
- authority’s discretion
Location
United Kingdom: Purchasing points listed at www.england.nhs.uk/publication/commercial-medicines-unit-pharmacy-purchasing-points-list
1 buyer
- NHS England Leeds
14 suppliers
- Mercury Pharmaceuticals London
- Accord Barnstaple
- Morningside Pharmaeuticals Loughborough
- Amarox Harrow
- Teva Castleford
- Bristol Myers Squibb Uxbridge
- Glenmark Pharmaceuticals Europe Watford
- Sandoz Camberley
- Wockhardt Wrexham
- Thornton & Ross Huddersfield
- Piramal Critical Care West Drayton
- Ranbaxy Uxbridge
- Mylan Hatfield
- Zentiva Pharma Guildford
Description
NHS National Generic Pharmaceuticals- LenalidomideOffer reference number: CM/PHG/21/5638Period of framework agreement: 01/09/2022 to 31/08/2023 (12 months) with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 48 months.Potential periods of call-offs under the framework agreement:Lenalidomide:ALL REGIONS: 01/09/2022 to 31/08/2023 (12 months)
Total Quantity or Scope
Invitation to offer for NHS National Generic Pharmaceuticals - LenalidomideOffer reference number: CM/PHG/21/5638Period of framework agreement: 01/09/2022 to 31/08/2023 (12 months) with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 48 months.Potential periods of call-offs under the framework agreement:Lenalidomide:ALL REGIONS: 01/09/2022 to 31/08/2023 (12 months) Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents
Award Detail
| 1 | Mercury Pharmaceuticals (London)
|
| 2 | Accord (Barnstaple)
|
| 3 | Morningside Pharmaeuticals (Loughborough)
|
| 4 | Amarox (Harrow)
|
| 5 | Teva (Castleford)
|
| 6 | Bristol Myers Squibb (Uxbridge)
|
| 7 | Glenmark Pharmaceuticals Europe (Watford)
|
| 8 | Sandoz (Camberley)
|
| 9 | Wockhardt (Wrexham)
|
| 10 | Thornton & Ross (Huddersfield)
|
| 11 | Piramal Critical Care (West Drayton)
|
| 12 | Ranbaxy (Uxbridge)
|
| 13 | Mylan (Hatfield)
|
| 14 | Zentiva Pharma (Guildford)
|
Renewal Options
Option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 48 months.
Award Criteria
| price | _ |
CPV Codes
- 33600000 - Pharmaceutical products
Indicators
- Options are available.
Other Information
** PREVIEW NOTICE, please check Find a Tender for full details. **
Reference
- ocds-h6vhtk-02ee98
- FTS 027452-2022